Barclays Forecasts Strong Price Appreciation for Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) had its price objective boosted by equities researchers at Barclays from $58.00 to $60.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. Barclays‘s target price would suggest a potential upside of 92.86% […]

Leave a Reply

Your email address will not be published.

Previous post Boyd Group Services (OTCMKTS:BYDGF) Raised to Moderate Buy at Royal Bank of Canada
Next post JFrog (NASDAQ:FROG) Price Target Raised to $38.00 at UBS Group